Search results
Results from the WOW.Com Content Network
Intercept said only one case of liver transplant was possibly related to the drug. The company, which holds the drug's U.S. commercial rights, was acquired by Italy's Alfasigma for nearly $800 ...
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) announced a summary of its actions to improve its capital position, including the recently announced private repurchases of senior secured convertible ...
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) announced additional positive data from its pivotal Phase 3 REGENERATE trial Wednesday. The trial is evaluating Intercept's obeticholic acid, or OCA ...
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary ...
Intercept said its treatment led to statistically significant reduction in fibrosis in patients with NASH after 18 months compared to the placebo, based on interim analysis. "Overall, we expect ...
The biotech turned in another strong quarterly performance with rising sales for Ocaliva and a regulatory filing for a new indication on the way.
Biotech and pharmaceutical companies in the New York metropolitan area represent a significant and growing economic component of the New York metropolitan area, [1] [2] the most populous combined statistical area in the United States [3] and one of the most populous megacities in the world.
Intercept (ICPT) enters into a settlement agreement with Dr. Reddy's for lead drug Ocaliva's generic version.